Physician profile
Mitzi Washington
NPI 1114909124
$1,279.12
in general payments reported to CMS, 2019-2025
20 companies · $70.15 in 2025
The $70.15 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $228 · 2021: $186 · 2022: $123 · 2023: $367 · 2024: $125 · 2025: $70.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $562.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $181.80 | 2019-2023 | Jornay Pm |
| Pfizer INC. | $138.04 | 2019-2025 | |
| Genentech USA, INC. | $124.01 | 2019-2020 | |
| Abbott Laboratories | $116.93 | 2023-2024 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $108.82 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.42 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $86.66 | 2021-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $79.03 | 2020 | |
| Glaxosmithkline, LLC. | $62.12 | 2019-2023 | Bexsero |
| Tris Pharma INC | $60.60 | 2023-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $52.36 | 2021-2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $34.24 | 2019 | |
| Alexion Pharmaceuticals, INC. | $26.09 | 2020 | |
| Seqirus USA INC | $18.51 | 2024 | Flucelvax, Fluad |
| Biomarin Pharmaceutical INC. | $18.49 | 2024 | Voxzogo 1.2mg |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $16.67 | 2023 | Azstarys |
| Genzyme Corporation | $16.51 | 2021 | |
| Lilly USA, LLC | $12.63 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.21 | 2019 | |
| Adlon Therapeutics L.P. | $10.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitzi Washington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.